Leung Gabriel - Jun 4, 2025 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Director
Signature
Steven Robbins, as attorney in fact for Leung, Gabriel
Stock symbol
NVCR
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/6/2025, 04:21 PM
Previous filing
Jun 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEUNG GABRIEL Director C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE Steven Robbins, as attorney in fact for Leung, Gabriel 2025-06-06 0001236183

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $0 +11.2K +13.81% $0.00 92.4K Jun 4, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Option (Right to Buy) Award $0 +16.7K $0.00 16.7K Jun 4, 2025 Ordinary Shares 16.7K $16.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.
F2 Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders.